24 Jul, EOD - Indian

SENSEX 80148.88 (-0.35)

Nifty 50 24413.5 (-0.27)

Nifty Bank 51317 (-0.89)

Nifty IT 40115.05 (0.18)

Nifty Midcap 100 56872.75 (1.04)

Nifty Next 50 71844.65 (0.30)

Nifty Pharma 20908.5 (0.74)

Nifty Smallcap 100 18723.5 (1.76)

24 Jul, EOD - Global

NIKKEI 225 39154.85 (-1.11)

HANG SENG 17311.05 (-0.91)

DOW JONES 39853.87 (-1.25)

S&P 5427.13 (-2.31)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(19 Jul 2024, 09:49)

Zydus Life Vadodara unit gets OAI report from USFDA

The US drug regulator conducted an inspection between 15 April 2024 and 23 April 2024.


Zydus Lifesciences informed that it has received a report from the United States Food and Drug Administration (USFDA) for the inspection conducted at its injectables manufacturing facility located at Jarod, near Vadodara, Gujarat.

Post inspection, the US FDA classified the facility as ‘Official Action Indicated’ (OAI).

The company said that it will work closely with the agency to resolve the regulatory status of this facility expeditiously.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The pharma major reported consolidated net profit of Rs 1,182.3 crore in Q4 FY24 steeply higher than Rs 296.6 crore recorded in Q4 FY23. Revenue from operations jumped 10.44% t...

More News
More Company News View Company Information